Welcome to LookChem.com Sign In|Join Free
  • or

50-78-2

Post Buying Request

50-78-2 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
CHemwill -- Acetyl Salicylic Acid BP/USP/EP/JP/ DC90/100Acetylsalicylic acid
Cas No: 50-78-2
USD $ 1.0-1.0 / Metric Ton 1 Metric Ton 1-500 Metric Ton/Day Chemwill Asia Co., Ltd. Contact Supplier
Bloom Tech (Since 2008) Factory Wholesale CAS 50-78-2 Acetylsalicylic Acid/Aspirin
Cas No: 50-78-2
USD $ 10.0-10.0 / Gram 1 Gram 3 Metric Ton/Month Shaanxi BLOOM TECH Co.,Ltd Contact Supplier
Acetylsalicylic acid Aspirin
Cas No: 50-78-2
No Data 1 Kilogram Metric Ton/Day Sunmore Healthcare Co., LTD. Contact Supplier
Top Supplier Aspirin/Acetyl Salicylic Acid CAS NO.50-78-2
Cas No: 50-78-2
USD $ 1.0-1.0 / Kilogram 25 Kilogram 100000 Kilogram/Year Shanghai Upbio Tech Co.,Ltd Contact Supplier
Aspirin/cas 50-78-2
Cas No: 50-78-2
USD $ 1.0-1.0 / Kilogram 1 Kilogram 2000 Metric Ton/Month Wuxi TAA Chemical Industry Co.,LTD. Contact Supplier
Acetylsalicylic acid aspirin usp ready stock BP EP 99% cas 50-78-2
Cas No: 50-78-2
No Data 1 Kilogram 1 Metric Ton/Day Hangzhou Fonlynn Health Technology Co., Ltd. Contact Supplier
Aspirin
Cas No: 50-78-2
No Data 1 Kilogram 100 Metric Ton/Month EnBridge PharmTech Co., Ltd. Contact Supplier
Aspirin
Cas No: 50-78-2
USD $ 2500.0-3000.0 / Kilogram 100 Kilogram 1000 Metric Ton/Month GUANGZHOU MEDCAN PHARMATECH LTD Contact Supplier
Acetylsalicylic acid
Cas No: 50-78-2
No Data No Data No Data SJZ THLD IMP & EXP CO LTD Contact Supplier
Acetylsalicylic acid Manufacturer/High quality/Best price/In stock
Cas No: 50-78-2
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier

50-78-2 Usage

How Aspirin is used in Ischemic Stroke therapy

In the therapy of Ischemic Stroke, 50 to 325 mg/day started between 24 and 48 hours after completion of alteplase has also been shown to reduce long-term death and disability. Aspirin, clopidogrel, and extended-release dipyridamole plus aspirin are all considered first-line antiplatelet agents. The combination of aspirin and clopidogrel can only be recommended in patients with ischemic stroke and a recent history of myocardial infarction or coronary stent placement and then only with ultra-low-dose aspirin to minimize bleeding risk.

Uses

Aspirin’s original use as an analgesic, an antipyretic, and to reduce inflammation continues to this day. More recently there is some evidence that aspirin lessens the chance of heart attacks as a result of its effect as a blood “thinner.”

Pharmacology

Although aspirin itself is pharmacologically active, it is rapidly hydrolyzed to salicylic acid after its absorption, and it is the salicylate anion that accounts for most of the anti-inflammatory activity of the drug. The superior analgesic activity of aspirin compared with sodium salicylate implies that aspirin has an intrinsic activity that is not totally explainable by its conversion to salicylic acid. Aspirin inhibits COX-1 to a much greater extent than COX-2; sodium salicylate is more selective for COX-1. This, combined with the ability of aspirin to acetylate proteins, might account for some of the therapeutic and toxicological differences between aspirin and the other salicylates. The binding of salicylic acid to plasma proteins varies with its plasma concentrations. At serum salicylic acid concentrations of less than 100 μg/mL, 90 to 95% is protein bound; at 100 to 400 μg/mL, 70 to 85% is protein bound; and at concentrations greater than 400 μg/mL, 20 to 60% is protein bound. The plasma concentration of salicylate that is associated with antiinflammatory activity (200–300 μg/mL) is about six times that needed to produce analgesia. At these higher concentrations, salicylate metabolism is reduced, resulting in a longer half-life for the drug. This reaction is a consequence of the saturable enzyme systems that metabolize salicylates. The plasma half-life for salicylate has been estimated to be 3 to 6 hours at the lower (analgesic) dosage and 15 to 30 hours at the higher (antiinflammatory) dosages.The rate of hydrolysis of aspirin to salicylic acid is not dose limited, and no differences in the absorption of aspirin have been observed between arthritic patients and normal individuals.

Clinical Use

Aspirin is used in the treatment of a number of conditions, including fever, pain, rheumatic fever, and inflammatory diseases, such as rheumatoid arthritis, pericarditis, and Kawasaki disease. Pain Asprin 325 MG for pain In most cases, aspirin is considered inferior to ibuprofen for the alleviation of pain, because aspirin is more likely to cause gastrointestinal bleeding . Aspirin is generally ineffective for those pains caused by muscle cramps, bloating, gastric distension, or acute skin irritation. Headache Aspirin, either by itself or in combined formulation, effectively treats some types of headache, but its efficacy may be questionable for others. Aspirin or other overthe- counter analgesics are widely recognized as effective for the treatment of tension headache. Aspirin, especially as a component of an acetaminophen/aspirin/caffeine formulation (e.g., Excedrin Migraine), is considered a first - line therapy in the treatment of migraine, and comparable to lower doses of sumatriptan. Fever Like its ability to control pain, aspirin's ability to control fever is due to its action on the prostaglandin system through its irreversible inhibition of COX . Heart attacks and strokes For a subset of the population, aspirin may help prevent heart attacks and strokes. In lower doses, aspirin has been known to prevent the progression of existing cardiovascular disease, and reduce the frequency of these events for those with a history of them . ( This is known as secondary prevention.) Post-surgery After percutaneous coronary interventions (PCIs), such as the placement of a coronary artery stent, a US Agency for Healthcare Research and Quality guideline recommends that aspirin be taken indefinitely.Frequently, aspirin is combined with an ADP receptor inhibitor, such as clopidogrel, prasugrel or ticagrelor to prevent blood clots. This is called dual anti-platelet therapy (DAPT).

Shipping

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required

Flammable hazardous characteristics

Flammable in fire; irritant gas would be decomposed out when heated.

Physical properties

Aspirin, an acetyl derivative of salicylic acid, is a white, crystalline, weakly acidic substance, with a melting point of 136 °C , and a boiling point of 140 °C . Synthesis The synthesis of aspirin is classified as an esterification reaction. Salicylic acid is treated with acetic anhydride, an acid derivative, causing a chemical reaction that turns salicylic acid's hydroxyl group into an ester group (R-OH → R-OCOCH3). This process yields aspirin and acetic acid, which is considered a byproduct of this reaction. Polymorphism Polymorphism, or the ability of a substance to form more than one crystal structure, is important in the development of pharmaceutical ingredients. Many drugs are receiving regulatory approval for only a single crystal form or polymorph. For a long time, only one crystal structure for aspirin was known. That aspirin might have a second crystalline form was suspected since the 1960s. The elusive second polymorph was first discovered by Vishweshwar and coworkers in 2005 , and fine structural details were given by Bond et al. .

Chemical Properties

White Solid

Side effects

Contraindications Aspirin should not be taken by people who are allergic to ibuprofen or naproxen , or who have salicylate intolerance[70][71] or a more generalized drug intolerance to NSAIDs, and caution should be exercised in those with asthma or NSAID - precipitated bronchospasm. Gastrointestinal Aspirin use has been shown to increase the risk of gastrointestinal bleeding . Although some enteric-coated formulations of aspirin are advertised as being "gentle to the stomach", in one study, enteric coating did not seem to reduce this risk. Combining aspirin with other NSAIDs has also been shown to further increase this risk. Central effects Large doses of salicylate, a metabolite of aspirin, have been proposed to cause tinnitus (ringing in the ears) based on experiments in rats, via the action on arachidonic acid and NMDA receptors cascade. 's syndrome ';s syndrome, a rare but severe illness characterized by acute encephalopathy and fatty liver, can occur when children or adolescents are given aspirin for a fever or other illnesses or infections.

Purification Methods

Crystallise aspirin twice from toluene, wash it with cyclohexane and dry it at 60o under vacuum for several hours [Davis & Hetzer J Res Nat Bur Stand 60 569 1958]. It has been recrystallised from isopropanol and from diethyl ether/pet ether (b 40-60o). It crystallises from EtOH (m 143-144o), *C6H6 (m 143o), hexane (m 115o and 128o), octane (m 121o), and has m 110o after sublimation. It has pK2 6 3.69(H2O), 4.15(20% aqueous EtOH), 4.47(30% aqueous EtOH) and 4.94(40% aqueous EtOH). It is an analgesic. [Beilstein 10 H 67, 10 II 41, 10 III 102, 10 IV 138.]

Description

Acetylsalicylic acid is a white crystalline powder commonly known by its common name as aspirin or ASA. Aspirin is the most widely used medication in the world.

General Description

Aspirin, acetylsalicylic acid (Aspro, Empirin), was introducedinto medicine by Dreser in 1899.Aspirin occurs as white crystals or as a white crystallinepowder and must be kept under dry conditions. It is not advisableto keep aspirin products in the kitchen or bathroomcabinets, because aspirin is slowly decomposed into aceticand salicylic acids in the presence of heat and moisture.Several proprietaries (e.g., Bufferin) use compounds such as sodium bicarbonate, aluminum glycinate, sodium citrate,aluminum hydroxide, or magnesium trisilicate to counteractaspirin’s acidic property. One of the better antacids is dihydroxyaluminumaminoacetate. Aspirin is unusually effectivewhen prescribed with calcium glutamate. The more stable,nonirritant calcium acetylsalicylate is formed, and theglutamate portion (glutamic acid) maintains a pH of 3.5 to5. Practically all salts of aspirin, except those of aluminumand calcium, are unstable for pharmaceutical use. Thesesalts appear to have fewer undesirable side effects and induceanalgesia faster than aspirin. A timed release preparationof aspirin is available. It does not appear to offer anyadvantages over aspirin, except for bedtime dosage.

Toxicity grading

High toxic

Chemical Synthesis

Aspirin, acetylsalicylic acid (3.2.2), is synthesized by the acetylation of salicylic acid (3.2.1) using acetic anhydride or acetyl chloride [60–63].

Chemical property

This product is a white crystalline, with melting point 138~140 ℃, insoluble in water, soluble in alcohol, ether, etc.

Category

Toxic substance

What’s acetylsalicylic acid?

Acetylsalicylic acid, also known as aspirin, is an analgesic-antipyretic medicine made by salicylic acid interacting with acetic anhydride. It is a white crystalline powder, odorless, stable in dry air. It will be slowly hydrolyzed to be salicylic acid and acetic acid in moist air, and aqueous solution has acidic reaction. Slightly soluble in water, soluble in ethanol, ethyl ether, chloroform, sodium hydroxide solution and sodium carbonate solution. Acetylsalicylic acid has antipyretic analgesic, anti-inflammatory and anti-rheumatism effect, that’s why it is often used for fever, headache, muscle pain, neuralgia, rheumatic fever, acute rheumatic arthritis, gout, etc.; also it has antiplatelet aggregation effect, and can be used for prevention of arterial thrombosis, atherosclerosis, transient cerebral ischemia and myocardial infarction; in addition, acetylsalicylic acid also can be used in the treatment of biliary tract roundworm disease and athlete's foot. Pharmacological actions Acetylsalicylic acid is one of the traditional antipyretic analgesics, as well as the role of platelet aggregation. Acetylsalicylic acid in the body has the characteristics of the antithrombotic, can reduce the formation of obstructive blood clots in surrounding arteries, and inhibit release of platelet response and endogenous ADP, 5-HT, etc., therefore to inhibit second phase other than the first phase of platelet aggregation. The mechanism of action of acetylsalicylic acid is to make platelets cyclooxygenase acetylation, thus inhibiting the formation of ring peroxide, and TXA2 formation is also reduced as well. At the mean time make the platelet membrane protein acetylation, and inhibit platelet membrane enzyme, which helps to inhibit platelet function. As the cyclooxygenase is inhibited, it impacts blood vessel wall synthesized to be PGI2, the platelet TXA2 synthetic enzymes also to be inhibited; so it would impact formation of both TXA2 and PGI2 when it is large doses. Suitable for ischemic heart disease, after percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, prevent transient ischemic stroke, myocardial infarction and reduce the incidence of arrhythmia. The above information is edited by the Chemicalbook He Liao Pu.

Manufacturing Process

As described in US Patent 2,731,492, a glass-lined reactor of 1,500 gallons capacity, fitted with a water-cooled reflux condenser, thermometers with automatic temperature registers and an efficient agitator, is employed. To start the process, a mother liquor is made by dissolving 1,532 kg of acetic anhydride (15 mols) in 1,200 kg of toluene. To this mother liquor, add 1,382 kg of salicylic acid (10 mols), heat the reaction mixture under an efficient reflux condenser, to 88-92°C and maintain within this temperature range for 20 hours. The reaction mixture is now transferred to aluminum cooling tanks, and is allowed to cool slowly, over a period of 3 to 4 days, to a terminal temperature of 15-25°C (room temperature). The acetylsalicylic acid precipitates as large, regular crystals. The mother liquor is now filtered or centrifuged from the precipitated acetylsalicylic acid and the filter cake is pressed or centrifuged as free of mother liquor as possible. The crystals are washed with distilled water until completely free of acetic acid, pressed or centrifuged as dry as possible and the filter cake is then dried in a current of warm air at a temperature of 60-70°C.The filtrate from this first batch will comprise a solution of 180 to 270 kg of unprecipitated acetylsalicylic acid (1.0 to 1.5 mols), 510 kg of acetic anhydride (5.0 mols), 600 kg of acetic acid (10.0 mols) (obtained as a byproduct in the acetylation step) and 1,200 kg of the diluent toluene. Into this filtrate, at a temperature of 15° to 25°C, ketene gas is now passed through a sparger tube or diffuser plate, with good agitation, until a weight increase of 420.5 kg of ketene (10 mols) occurs. The reaction mixture will now contain 180-270 kg of unprecipitated acetylsalicylic acid (1.0-1.5 mols) and 1,532 kg of acetic anhydride (15 mols) in 1,200 kg of toluene. This mother liquor is recycled to the first step of the process for reaction with another batch of 1,382 kg of salicylic acid. On recirculating the mother liquor, the yield of pure acetylsalicylic acid is 1,780 to 1,795 kg per batch.

Uses

Axepim Cephalosporin antibiotic

Acquired resistance

Aspirin is rapidly absorbed in the stomach and quickly degraded by plasma cholinesterases (half-life, 15–20 min). A once-daily dose of 160 mg of aspirin, which is much lower than dosages needed for its anti-inflammatory/analgesic actions, is sufficient to completely inactivate platelet COX-1 irreversibly. Higher doses of aspirin only contribute to its side effects, especially internal bleeding and upper gastrointestinal irritations.

Production method

Acetylation of salicylic acid: add acetic anhydride (feeding ratio is 0.7889 times of the total salicylic acid) in reaction vessel, and then add two thirds of salicylic acid, stir it and temperature rises. React 40-60min in 81-82℃. Cool it to 81-82 ℃ and keep the temperature for 2h. When free salicylic acid is qualified, cool it to 13 ℃, precipitation crystallization, rejection filter, dry it in 65-70℃ air flow, then we get acetylsalicylic acid.

World Health Organization (WHO)

Acetylsalicylic acid, a nonsteroidal anti-inflammatory, analgesic and antipyretic agent, was introduced into medicine in 1899 and has since been widely available in over-the-counter preparations. Recent studies carried out in the USA have shown an association between acetylsalicylic acid consumption in children and the development of Reye's syndrome (a rare condition characterized by a combination of encephalopathy and liver disorder and usually preceded by an acute viral illness, such as influenza, diarrhoea, or chickenpox). Many drug regulatory authorities have acted to caution against the use of the drug in children and young adults with febrile conditions. Even within this group the risk of exposure is remote and has been estimated to be of the order of 1.5 per million. This warning also concerns products containing other salicylates. The new indication of acetylsalicylic acid - prophylaxis of myocardial infarction due to its antithrombotic effect - requires loneterm use and may lead to serious adverse reactions, including cerebral haemorrhage. Acetylsalicylic acid retains a valuable place in medicine and remains in the WHO Model List of Essential Drugs.

Air & Water Reactions

Slowly hydrolyzes in moist air. Has been involved in dust cloud explosions. Water insoluble. Solution in water is acid to methyl red indicator.

History

The use of salicylic acid goes back thousands of years, and there are numerous accounts of the medicinal properties of plants from the Salix (willow) and Myrtaceae (Myrtle) families. Writings from ancient civilizations indicate the use of willow bark in Mesopotamia and myrtle leaves in Egypt as medicines existing several thousand years b.c.e. Hippocrates (460–377 b.c.e. ) and the ancient Greeks used powdered willow bark and leaves to reduce fever (antipyretic) and as a pain reliever (analgesic). Willow and oil of wintergreen was used as medications by native Americans. The chemical responsible for the medicinal properties in willow and oil of wintergreen are forms of salicylates, a general name to describe compounds containing the general structure of salicylic acid. Willows (genus Salix) contain salicin and oil of wintergreen contains methyl salicylate. Although the use of willow bark and oil of wintergreen as an accepted antipyretic and analgesic has occurred for at least 2,000 years, by the 19th century medicines were starting to be synthesized in chemical laboratories.

Occupational standard

TWA 5 mg/m3

General Description

Odorless white crystals or crystalline powder with a slightly bitter taste.

Chemical Properties

Aspirin (USAN), also known as acetyl salicylic acid (abbreviated ASA ) , is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti - inflammatory medication. Aspirin may be effective at preventing certain types of cancer, particularly colorectal cancer. The main undesirable side effects of aspirin taken by mouth are gastrointestinal ulcers, stomach bleeding, and tinnitus, especially in higher doses. In children and adolescents, aspirin is no longer indicated to control flu - like symptoms or the symptoms of chickenpox or other viral illnesses, because of the risk of Reye's syndrome. Aspirin is part of a group of medications called non steroidal anti - inflammatory drugs (NSAIDs), but differs from most other NSAIDs in the mechanism of action. Though it, and others in its group called the salicylates, have similar effects (antipyretic, antiinflammatory, analgesic) to the other NSAIDs and inhibit the same enzyme cyclooxygenase, aspirin (but not the other salicylates) does so in an irreversible manner and, unlike others, affects more the COX-1 variant than the COX-2 variant of the enzyme. Today, aspirin is one of the most widely used medications in the world, with an estimated 40,000 tonnes of it being consumed each year . In countries where Aspirin is a registered trademark owned by Bayer, the generic term is acetylsalicylic acid (ASA).

Uses

antifungal

Waste Disposal

May be flushed to sewer with large volumes of water.

Uses

1.Acetylsalicylic acid is the raw material for rodenticide intermediates 4-hydroxycoumarin. 2.Used to make outdoor structural members and equipment parts exposed in highlights, such as the automobile body, agricultural machinery parts, meters and electric lamps, road marking, etc. 3.It is the earliest applied, the most popular and the most common antipyretic analgesics anti-rheumatism medicine, has aspects of pharmacological effects as antipyretic-analgesic and anti-inflammatory, anti-platelet aggregation and works quickly and effectively. Overdosage can be easily diagnosed and treated, with rare allergic reactions. Often used to cold fever, headache, neuralgia, joint ache, muscle pain, rheumatic fever, acute wet sex arthritis, rheumatoid arthritis and toothache, etc. Listed in National Essential Medicine List. Acetylsalicylic acid also works as an intermediate of other medicines.

Indications

Aspirin is available as capsules, tablets, enteric-coated tablets (Ecotrin), timed-release tablets (ZORprin), buffered tablets (Ascriptin, Bufferin), and as rectal suppositories. Sodium salicylate is available generically. Other salicylates include choline salicylate (Arthropan), choline magnesium trisalicylate (Trilisate), and magnesium salicylate (Momentum).

Originator

Entab,Mayrand,US,1982

Chemical Properties

Acetylsalicylic acid is a white crystalline solid with a slightly bitter taste. It is odorless but hydrolyzes in moist air to give an acetic acid odor

Handling and storage characteristics

Warehouse needs to be ventiIative and dry with low temperature; separate it from oxidant and food additives.

Fire Hazard

Acetylsalicylic acid is combustible.

Acute toxicity

Oral-rat LD50: 200 mg/kg; Oral-mice LD50: 250 mg/kg

Safety Profile

Poison by ingestion, intraperitoneal, and possibly other routes. Human systemic effects by ingestion: acute pulmonary edema, body temperature increase, changes in kidney tubules, coma, constipation, dehydration, hematuria, hepatitis, nausea or vomiting, respiratory stimulation, somnolence, tinnitus, decreased urine volume. Implicated in aplastic anemia. A 10 gram dose to an adult may be fatal. A human teratogen. Human reproductive effects by ingestion and possibly other routes: menstrual cycle changes, parturition, various effects on newborn including Apgar score, developmental abnormalities of the cardlovascular and respiratory systems. Experimental animal reproductive effects. Human mutation data reported. An allergen; skin contact, inhalation, or ingestion can cause asthma, sneezing, irritation of eyes and nose, hves, and eczema. Combustible when exposed to heat or flame. When heated to decomposition it emits acrid smoke and fumes.

Reactivity Profile

The active ingredient in common aspirin. Incompatible with oxidizers and strong acids. Also incompatible with strong bases. May react with water or nucleophiles (e.g. amines and hydroxy groups). May also react with acetanilide, amidopyrine, phenazone, hexamine, iron salts, phenobarbitone sodium, quinine salts, potassium and sodium iodides, alkali hydroxides, carbonates, stearates and paracetanol.

General Description

Aspirin, acetylsalicylic acid, has an inhibitoryeffect on platelet aggregation not only because of its abilityto inhibit cyclooxygenase (COX) but also because of its ability to acetylate the enzyme. Aspirin irreversibly inhibitsCOX (prostaglandin H synthase), which is the enzyme involvedin converting arachidonate to prostaglandin G2 andultimately thromboxane 2, an inducer of platelet aggregation.Aspirin’s mechanism of action includes not only the inhibitionin the biosynthesis of thromboxane 2, but also itsability to acetylate the serine residue (529) in the polypeptidechain of platelet prostaglandin H synthetase-1. Thisexplains why other nonsteroidal anti-inflammatory agentsthat are capable of inhibiting the COX enzyme do not act asantithrombotics—they are not capable of acetylating thisenzyme. Because platelets cannot synthesize new enzymes,aspirin’s ability to acetylate COX lasts for the life of theplatelet (7–10 days) and is, thus, irreversible.

Pharmacology

Salicylic acid is a weak acid, and very little of it is ionized in the stomach after oral administration. Acetylsalicylic acid is poorly soluble in the acidic conditions of the stomach, which can delay absorption of high doses for eight to 24 hours. The increased pH and larger surface area of the small intestine causes aspirin to be absorbed rapidly there, which in turn allows more of the salicylate to dissolve. Owing to the issue of solubility, however, aspirin is absorbed much more slowly during overdose, and plasma concentrations can continue to rise for up to 24 hours after ingestion.

Uses

Analgesic; antipyretic; anti-inflammatory; antithrombotic

Fire extinguishing agent

Water fog, foam, carbon dioxide, sandy soil.

Brand name

Aspirin;Compralgyl;Melabon;Rumicine;Salipran;Spalt;Tapal;Zorprin.

Potential Exposure

Used as an over-the counter and proprietary pharmaceutical and veterinary drug. Those engagedin manufacture of aspirin or, more likely, in its consumption in widespread use as an analgesic, antipyretic, and antiinflammatory agent

Side effects

The most common adverse effects produced by the salicylates are GI disturbances. Occult blood loss from the GI tract, peptic ulceration, and rarely, severe GI hemorrhage can occur. Because salicylic acid is highly bound to plasma proteins, it may be displaced by other highly protein-bound drugs such as oral anticoagulants, sulfonylureas, phenytoin, penicillins, and sulfonamides. The nonacetylated salicylates have greatly reduced effects on blood loss and produce fewer adverse GI effects. In addition, they may be somewhat kidney sparing. Salicylates may provoke hypersensitivity reactions and prolonged bleeding time in some individuals. Tinnitus, hearing impairment, blurred vision, and lightheadedness are indicators of toxic dosages. The use of aspirin in conjunction with any other NSAID is not recommended because of the lack of evidence that such combinations increase efficacy and because of the increased potential for an adverse reaction. Salicylates are contraindicated in children with febrile viral illnesses because of a possible increased risk of Reye’s syndrome.

Hazard

An allergen; may cause local bleeding espe- cially of the gums; 10-g dose may be fatal. May cause excessive biosynthesis of prostaglandins. Dust dispersed in air is serious explosion risk. Skin and eye irritant.

Incompatibilities

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides, carbonates, moisture. Dust dispersed in air is explosive

Biological Functions

Aspirin is one of the most important NSAIDs because it decreases pain at predominantly peripheral sites with little cortical interaction and thus has few CNS effects. The prototypical COX-2 inhibitors are celecoxib (Celebrex) and its chemical cousin, rofecoxib (Vioxx). In addition to a role in inflammatory processes,COX-2 seems to play a role in colon cancer and Alzheimer’s disease, providing potential additional uses for COX-2-selective drugs.

Definition

ChEBI: A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with moA cyclooxygenase inhibitor activity.

Mechanism of action

Discovery of the mechanism In 1971, British pharmacologist John Robert Vane, then employed by the Royal College of Surgeons in London, showed aspirin suppressed the production of prostaglandins and thromboxanes. Suppression of prostaglandins and thromboxanes Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the cyclo oxygenase (PTGS) enzyme required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the PTGS enzyme. COX-1 and COX-2 inhibition There are at least two different types of cyclooxygenase: COX-1 and COX-2. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. Aspirin-modified PTGS2 produces lipoxins, most of which are anti-inflammatory. Additional mechanisms Aspirin has been shown to have at least three additional modes of action. It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons . In short, aspirin buffers and transports the protons. When high doses of aspirin are given, it may actually cause fever, owing to the heat released from the electron transport chain, as opposed to the antipyretic action of aspirin seen with lower doses. Hypothalamic - pituitary - adrenal activity Aspirin, like other medications affecting prostaglandin synthesis, has profound effects on the pituitary gland, which indirectly affects a number of other hormones and physiological functions.

Therapeutic Function

Analgesic, Antipyretic, Antiinflammatory
InChI:InChI=1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)/p-1

50-78-2 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
TCI America (A2262)  Acetylsalicylic Acid  >98.0%(GC)(T) 50-78-2 25g 98.00CNY Detail
TCI America (A2262)  Acetylsalicylic Acid  >98.0%(GC)(T) 50-78-2 500g 295.00CNY Detail
Alfa Aesar (A12488)  O-Acetylsalicylic acid, 99%    50-78-2 100g 99.0CNY Detail
Alfa Aesar (A12488)  O-Acetylsalicylic acid, 99%    50-78-2 500g 275.0CNY Detail
Alfa Aesar (A12488)  O-Acetylsalicylic acid, 99%    50-78-2 2500g 733.0CNY Detail
Sigma-Aldrich (PHR1003)  Aspirin (Acetyl Salicylic Acid)  pharmaceutical secondary standard; traceable to USP, PhEur and BP 50-78-2 PHR1003-1G 732.19CNY Detail
Sigma-Aldrich (A0200000)  Acetylsalicylicacid  European Pharmacopoeia (EP) Reference Standard 50-78-2 A0200000 1,880.19CNY Detail
Sigma-Aldrich (Y0001460)  Acetylsalicylic acid for peak identification  European Pharmacopoeia (EP) Reference Standard 50-78-2 Y0001460 1,880.19CNY Detail
USP (1044006)  Aspirin  United States Pharmacopeia (USP) Reference Standard 50-78-2 1044006-500MG 4,662.45CNY Detail
Sigma (A3160)  Acetylsalicylicacid  analytical standard 50-78-2 A3160-1VL 1,173.51CNY Detail
Sigma (A3160)  Acetylsalicylicacid  analytical standard 50-78-2 A3160-5X1VL 4,699.89CNY Detail

50-78-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name acetylsalicylic acid

1.2 Other means of identification

Product number -
Other names 2-Acetoxybenzoic acid,O-Acetylsalicylic acid,ASA

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:50-78-2 SDS

50-78-2Synthetic route

acetic anhydride
108-24-7

acetic anhydride

salicylic acid
69-72-7

salicylic acid

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
In neat (no solvent) Molecular sieve; Microwave irradiation; Green chemistry;100%
With erbium(III) chloride for 0.2h; Heating;99%
With SO42-/ZrO2*graphene oxide solid super acid catalyst at 70℃; for 5h; Reagent/catalyst; Green chemistry;97.1%
methylene-benzo[1,3]dioxin-4-one
302353-24-8

methylene-benzo[1,3]dioxin-4-one

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With water at 25℃; for 1h; pH=7;100%
acetic acid
64-19-7

acetic acid

salicylic acid
69-72-7

salicylic acid

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
at 80 - 90℃;95%
With sulfuric acid at 70℃; for 5h; Reagent/catalyst;95.7%
2-thioacetoxy-benzoic acid

2-thioacetoxy-benzoic acid

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With thionyl chloride; dihydrogen peroxide In ethanol at 25℃; for 0.0166667h;95%
With chloro-trimethyl-silane; dihydrogen peroxide In ethanol; water at 25℃; for 0.0666667h; regioselective reaction;88%
With Oxone for 0.583333h;58%
acetyl chloride
75-36-5

acetyl chloride

salicylic acid
69-72-7

salicylic acid

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With triethylamine In dichloromethane at 0 - 20℃;86%
With pyridine; sulfuric acid Cooling with ice;59.23%
methoxymethyl 2-acetoxybenzoate

methoxymethyl 2-acetoxybenzoate

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With bismuth(III) chloride; water In acetonitrile at 50℃; for 1h;85%
2-methylphenyl acetate
533-18-6

2-methylphenyl acetate

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With zinc(II) oxide In N,N-dimethyl-formamide for 0.15h; microwave irradiation;80%
With potassium permanganate; benzyl(triethyl)ammoniumpermanganate In acetic acid at 30℃; for 72h;24%
With 2,2'-azobis(isobutyronitrile); oxygen; 1N,3N,5N-trihydroxy-1,3,5-triazin-2,4,6[1H,3H,5H]-trione; cobalt(II) acetate; manganese(II) acetate In acetic acid at 150℃; under 760 Torr; for 14h;9%
C16H16N2O5S
85515-88-4

C16H16N2O5S

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With copper dichloride In tetrahydrofuran; water for 24h; Ambient temperature;80%
acetic anhydride
108-24-7

acetic anhydride

4'-Methoxy-flavyliumchlorid
15402-17-2

4'-Methoxy-flavyliumchlorid

A

4-methoxybenzoic acid
100-09-4

4-methoxybenzoic acid

B

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With ruthenium(IV) oxide; sodium periodate 1) 5 h, room temp., pyridine; 2) acetic ester, water, 20 min : decomposition reaction;A 79%
B 52%
With ruthenium(IV) oxide; sodium periodate 1) 5 h, room temp., pyridine; 2) water, acetic ester, 20 min; Yield given. Multistep reaction. Yields of byproduct given;
O-acetylsalicylic acid acid 2-oxo-1,2,2-triphenylethyl ester
925681-78-3

O-acetylsalicylic acid acid 2-oxo-1,2,2-triphenylethyl ester

A

13-oxa-indeno[1,2-l]phenanthrene
201-68-3

13-oxa-indeno[1,2-l]phenanthrene

B

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With air In ethanol; acetonitrile Irradiation;A n/a
B 79%
acetic anhydride
108-24-7

acetic anhydride

salicylaldehyde
90-02-8

salicylaldehyde

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With oxygen; CoCl2 In 1,2-dichloro-ethane at 25℃; other aldehydes;71.5%
With oxygen; CoCl2 In 1,2-dichloro-ethane at 25℃;71.5%
With oxygen; cobalt(II) chloride In 1,2-dichloro-ethane at 25℃; for 20h;71%
tert-butyl acetylperoxysalicylate
52602-01-4

tert-butyl acetylperoxysalicylate

A

2-acetoxybiphenyl
3271-80-5

2-acetoxybiphenyl

B

Phenyl acetate
122-79-2

Phenyl acetate

C

salicylic acid
69-72-7

salicylic acid

D

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
In benzene at 100℃; for 48h;A 36%
B 10%
C 42%
D 12%
methyl acetylsalicylate
580-02-9

methyl acetylsalicylate

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With lithium chloride In N,N-dimethyl-formamide for 0.166667h; Microwave irradiation; chemoselective reaction;34%
Stage #1: methyl acetylsalicylate With sodium hydroxide In methanol; water for 2h; Reflux;
Stage #2: With hydrogenchloride
(Z)-1-acetoxy-1-(2-acetoxyphenyl)-1,3-butadiene
129218-88-8

(Z)-1-acetoxy-1-(2-acetoxyphenyl)-1,3-butadiene

A

2-methyl-3-(phenylmethyl)chromone
129218-93-5

2-methyl-3-(phenylmethyl)chromone

B

(E)-1-acetoxy-1-(2-acetoxyphenyl)-1,3-butadiene
129218-92-4

(E)-1-acetoxy-1-(2-acetoxyphenyl)-1,3-butadiene

C

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
In hexane for 2h; Ambient temperature; Irradiation;A 7%
B 30%
C 23%
acetic anhydride
108-24-7

acetic anhydride

salicylic acid
69-72-7

salicylic acid

benzene
71-43-2

benzene

aspirin
50-78-2

aspirin

(2-acetoxy-benzoic acid )-acetic acid-anhydride
18698-59-4

(2-acetoxy-benzoic acid )-acetic acid-anhydride

acetic acid
64-19-7

acetic acid

A

acetic anhydride
108-24-7

acetic anhydride

B

aspirin
50-78-2

aspirin

acetic acid
64-19-7

acetic acid

dibenzoyl peroxide
94-36-0

dibenzoyl peroxide

A

benzoic acid
65-85-0

benzoic acid

B

Phenyl acetate
122-79-2

Phenyl acetate

C

aspirin
50-78-2

aspirin

D

benzene
71-43-2

benzene

sodium salicylate
54-21-7

sodium salicylate

acetyl chloride
75-36-5

acetyl chloride

aspirin
50-78-2

aspirin

Ketene
463-51-4

Ketene

acetone
67-64-1

acetone

salicylic acid
69-72-7

salicylic acid

A

(2-acetoxy-benzoic acid )-acetic acid-anhydride
18698-59-4

(2-acetoxy-benzoic acid )-acetic acid-anhydride

B

aspirin
50-78-2

aspirin

Ketene
463-51-4

Ketene

diethyl ether
60-29-7

diethyl ether

salicylic acid
69-72-7

salicylic acid

aspirin
50-78-2

aspirin

Ketene
463-51-4

Ketene

diethyl ether
60-29-7

diethyl ether

salicylic acid
69-72-7

salicylic acid

A

(2-acetoxy-benzoic acid )-acetic acid-anhydride
18698-59-4

(2-acetoxy-benzoic acid )-acetic acid-anhydride

B

aspirin
50-78-2

aspirin

Ketene
463-51-4

Ketene

salicylic acid
69-72-7

salicylic acid

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With acetone Behandeln des Reaktionsgemisches mit Wasser;
With acetone Erwaermen des Reaktionsprodukts mit Essigsaeure;
With diethyl ether
With acetone Erwaermen des Reaktionsprodukts mit Essigsaeure;
ethylidene diacetate
542-10-9

ethylidene diacetate

salicylic acid
69-72-7

salicylic acid

aspirin
50-78-2

aspirin

1,1-diacetoxy-2-propene
869-29-4

1,1-diacetoxy-2-propene

salicylic acid
69-72-7

salicylic acid

A

2-vinyl-4H-benzo[d][1,3]dioxin-4-one

2-vinyl-4H-benzo[d][1,3]dioxin-4-one

B

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With sulfuric acid; acetic acid at 105℃;
dibenzoyl peroxide
94-36-0

dibenzoyl peroxide

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With acetic acid at 90℃;
2-tert-butoxy-2-methyl-4H-1,3-benzodioxin-4-one
52602-20-7

2-tert-butoxy-2-methyl-4H-1,3-benzodioxin-4-one

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With phosphate buffer In 1,4-dioxane; water at 37℃; Rate constant;
L-Cysteine
52-90-4

L-Cysteine

aspirin anhydride
1466-82-6

aspirin anhydride

A

S-(O-acetylsalicyloyl)-2-amino-3-thiopropionic acid

S-(O-acetylsalicyloyl)-2-amino-3-thiopropionic acid

B

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
In 1,4-dioxane; water Rate constant; sodium acetate buffer;;
N-acetylcystein
616-91-1

N-acetylcystein

aspirin anhydride
1466-82-6

aspirin anhydride

A

2-acetamido-3-(2-acetoxybenzoylthio)propionic acid

2-acetamido-3-(2-acetoxybenzoylthio)propionic acid

B

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
In 1,4-dioxane; water Rate constant; sodium acetate buffer;;
2-oxopropyl 2-acetoxybenzoate
50785-25-6

2-oxopropyl 2-acetoxybenzoate

A

Salicylsaeure-2-oxopropylester
2100-38-1

Salicylsaeure-2-oxopropylester

B

aspirin
50-78-2

aspirin

Conditions
ConditionsYield
With buffer pH 8.0 In acetonitrile at 37℃; Kinetics; half-life time of hydrolysis at different pH;
aspirin
50-78-2

aspirin

aspirin anhydride
1466-82-6

aspirin anhydride

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In dichloromethane at 20℃;100%
With iodine; triethylamine; triphenylphosphine In dichloromethane at 0 - 20℃;72%
With triethylamine; trichloroacetonitrile; triphenylphosphine In tetrahydrofuran at 20℃; for 2h;71%
aspirin
50-78-2

aspirin

O-acetylsalicyloyl chloride
5538-51-2

O-acetylsalicyloyl chloride

Conditions
ConditionsYield
Stage #1: aspirin With oxalyl dichloride In dichloromethane at 20℃; for 0.5h;
Stage #2: In dichloromethane; N,N-dimethyl-formamide at 20℃; for 6h;
100%
With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 3h;98.5%
With 2-hydroxypyridin; thionyl chloride In chloroform at 80 - 85℃;97%
aspirin
50-78-2

aspirin

phosphorous acid trimethyl ester
121-45-9

phosphorous acid trimethyl ester

dimethyl 1-(2-acetoxyphenyl)-1-oxomethanephosphonate
62880-92-6

dimethyl 1-(2-acetoxyphenyl)-1-oxomethanephosphonate

Conditions
ConditionsYield
Stage #1: aspirin With oxalyl dichloride In dichloromethane at 20℃;
Stage #2: phosphorous acid trimethyl ester at 5 - 20℃; Further stages.;
100%
aspirin
50-78-2

aspirin

benzyl alcohol
100-51-6

benzyl alcohol

2-acetoxybenzoic acid benzyl ester
52602-17-2

2-acetoxybenzoic acid benzyl ester

Conditions
ConditionsYield
With di-isopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran at 0℃; for 1h; Reagent/catalyst; Solvent; Temperature; Mitsunobu Displacement; Inert atmosphere;100%
t-butyldimethylsilyl amine
41879-37-2

t-butyldimethylsilyl amine

aspirin
50-78-2

aspirin

tert-butyldimethylsilyl 2-acetoxybenzoate
129512-44-3

tert-butyldimethylsilyl 2-acetoxybenzoate

Conditions
ConditionsYield
In neat (no solvent) at 20℃; for 0.5h; Green chemistry;100%
zyprexa
132539-06-1

zyprexa

aspirin
50-78-2

aspirin

C7H6O3*C17H20N4S
929209-00-7

C7H6O3*C17H20N4S

Conditions
ConditionsYield
In methanol for 24h; Product distribution / selectivity;99%
triethanolamine
102-71-6

triethanolamine

aspirin
50-78-2

aspirin

triethanolamine salicylate
2174-16-5

triethanolamine salicylate

Conditions
ConditionsYield
With methanol for 1h; Reflux;99%
aluminum ethoxide
555-75-9

aluminum ethoxide

aspirin
50-78-2

aspirin

Al(OC2H5)(C6H4OCOCH3COO)2
198878-22-7

Al(OC2H5)(C6H4OCOCH3COO)2

Conditions
ConditionsYield
In xylene acid heated until dissolved (80-85°C), further heating (90-95°C), alcoholate addn., stirring (90-95°C, 3-4 h); drying in vacuum; elem. anal.;98.5%
phenylacetylene
536-74-3

phenylacetylene

aspirin
50-78-2

aspirin

(Z)-β-Styryl acetylsalicylate

(Z)-β-Styryl acetylsalicylate

Conditions
ConditionsYield
Ru(η3-CH2=C(Me)CH2)2 In toluene at 80℃; for 20h;98%
phenylacetylene
536-74-3

phenylacetylene

aspirin
50-78-2

aspirin

1-phenylvinyl 2-acetoxybenzoate

1-phenylvinyl 2-acetoxybenzoate

Conditions
ConditionsYield
With C58H34F18O6P2Ru; silver trifluoromethanesulfonate In toluene at 70℃; for 2h; Inert atmosphere; Schlenk technique; regioselective reaction;98%
aluminum isopropoxide
555-31-7

aluminum isopropoxide

aspirin
50-78-2

aspirin

Al(OC3H7)(C6H4OCOCH3COO)2
198878-23-8

Al(OC3H7)(C6H4OCOCH3COO)2

Conditions
ConditionsYield
In xylene acid heated until dissolved (80-85°C), further heating (90-95°C), alcoholate addn., stirring (90-95°C, 3-4 h); drying in vacuum; elem. anal.;97.8%
vanadocene

vanadocene

aspirin
50-78-2

aspirin

cyclopentadienylvanadium bisacetylsalicylate

cyclopentadienylvanadium bisacetylsalicylate

Conditions
ConditionsYield
In diethyl ether byproducts: C5H6, H2; (vac. or Ar); addn. of acid to V-complex in ether (20°C, 24 h); filtration, washing (ether), drying; elem. anal.;97%
3-hydroxyimino-olean-12-en-28-oic acid
49815-49-8

3-hydroxyimino-olean-12-en-28-oic acid

aspirin
50-78-2

aspirin

17,3-(2-acetoxy)benzoyloxyiminoolean-12-en-28-oic acid

17,3-(2-acetoxy)benzoyloxyiminoolean-12-en-28-oic acid

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In 1,4-dioxane at 20℃;96.9%
With dicyclohexyl-carbodiimide In chloroform at 0 - 20℃; for 2h;62%
With dicyclohexyl-carbodiimide In 1,4-dioxane at 20℃;
aluminum isopropoxide
555-31-7

aluminum isopropoxide

aspirin
50-78-2

aspirin

Al(C6H4OCOCH3COO)3
29825-08-9

Al(C6H4OCOCH3COO)3

Conditions
ConditionsYield
In xylene acid heated until dissolved (80-85°C), further heating (90-95°C), alcoholate addn., stirring (90-95°C, 3-4 h); drying in vacuum; elem. anal.;96.5%
aluminum isopropoxide
555-31-7

aluminum isopropoxide

aspirin
50-78-2

aspirin

Al(OC3H7)2C6H4OCOCH3COO
198878-21-6

Al(OC3H7)2C6H4OCOCH3COO

Conditions
ConditionsYield
In xylene acid heated until dissolved (80-85°C), further heating (90-95°C), alcoholate addn., stirring (90-95°C, 3-4 h); drying in vacuum; elem. anal.;96%
2,2'-iminobis[ethanol]
111-42-2

2,2'-iminobis[ethanol]

aspirin
50-78-2

aspirin

bis(2-hydroxy-ethyl)ammonium 2-hydroxy-benzoate
109962-24-5

bis(2-hydroxy-ethyl)ammonium 2-hydroxy-benzoate

Conditions
ConditionsYield
With methanol for 1h; Reflux;96%
2-(Diethylamino)ethanol
100-37-8

2-(Diethylamino)ethanol

aspirin
50-78-2

aspirin

diethylaminoethylacetylsalicylate acetylsalicylate

diethylaminoethylacetylsalicylate acetylsalicylate

Conditions
ConditionsYield
Stage #1: aspirin With dicyclohexyl-carbodiimide In chloroform at 5 - 20℃; for 2h;
Stage #2: 2-(Diethylamino)ethanol at 20℃; for 3h;
96%
2-(Diethylamino)ethanol
100-37-8

2-(Diethylamino)ethanol

aspirin
50-78-2

aspirin

diethylaminoethyl acetylsalicylate acetylsalicylic acid salt

diethylaminoethyl acetylsalicylate acetylsalicylic acid salt

Conditions
ConditionsYield
Stage #1: aspirin With dicyclohexyl-carbodiimide In chloroform at 5 - 20℃; for 2h;
Stage #2: 2-(Diethylamino)ethanol In chloroform at 20℃; for 3h;
96%
Stage #1: aspirin With dicyclohexyl-carbodiimide In chloroform at 5 - 20℃; for 2h;
Stage #2: 2-(Diethylamino)ethanol In chloroform at 20℃; for 3h;
96%
ethambutol
74-55-5

ethambutol

aspirin
50-78-2

aspirin

C19H30N2O5

C19H30N2O5

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dimethyl sulfoxide at 30℃; Temperature;96%
fluoroiodomethane
373-53-5

fluoroiodomethane

aspirin
50-78-2

aspirin

fluoromethyl 2-acetoxybenzoate

fluoromethyl 2-acetoxybenzoate

Conditions
ConditionsYield
With caesium carbonate In acetonitrile at 20℃; for 6h; chemoselective reaction;96%
exo-7-chloro-endo-7-phenyl-cis-bicyclo<4.2.0>octan-8-one
103150-19-2

exo-7-chloro-endo-7-phenyl-cis-bicyclo<4.2.0>octan-8-one

aspirin
50-78-2

aspirin

exo-1-<(2-acetoxybenzoyl)oxy>-7-phenyl-cis-bicyclo<4.2.0>octane-8-one
122898-94-6

exo-1-<(2-acetoxybenzoyl)oxy>-7-phenyl-cis-bicyclo<4.2.0>octane-8-one

Conditions
ConditionsYield
With triethylamine In acetone at 20℃;95%
aspirin
50-78-2

aspirin

salicylic acid
69-72-7

salicylic acid

Conditions
ConditionsYield
With water; trifluoroacetic acid at 65℃; for 0.5h;95%
With copper dichloride In methanol; water for 1h; Heating;90%
With sodium hydroxide In 1,4-dioxane at 56.4℃; Rate constant; pH 12; reaction in the presence of aq. cetyltrimethylammonium bromide (CTBA);
2,3,4,5,6-pentafluorophenol
771-61-9

2,3,4,5,6-pentafluorophenol

aspirin
50-78-2

aspirin

2-acetoxy-benzoic acid pentafluorophenyl ester
65482-79-3

2-acetoxy-benzoic acid pentafluorophenyl ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 40℃; for 0.333333h; microwave irradiation;95%
With dicyclohexyl-carbodiimide In 1,4-dioxane for 4h;61%
propargyl bromide
106-96-7

propargyl bromide

aspirin
50-78-2

aspirin

Acetylsalicylic acid propargylic ester

Acetylsalicylic acid propargylic ester

Conditions
ConditionsYield
With sodium hydride In N,N-dimethyl-formamide at 0 - 20℃; for 2h;95%
With potassium carbonate In N,N-dimethyl-formamide at 20℃;
Stage #1: aspirin With potassium carbonate In N,N-dimethyl-formamide for 0.5h;
Stage #2: propargyl bromide In N,N-dimethyl-formamide at 60℃; for 10h;
aspirin
50-78-2

aspirin

lysine Acetylsalicylate
62952-06-1

lysine Acetylsalicylate

Conditions
ConditionsYield
In ethanol; water for 0.533333h; Time;95%
In water; acetone at -15 - 15℃; for 1h; Concentration;92.4%
3-hydroxyimino-olean-12-en-28-oic acid methyl ester
35137-30-5

3-hydroxyimino-olean-12-en-28-oic acid methyl ester

aspirin
50-78-2

aspirin

13,3-(2-acetoxy)benzoyloxyiminoolean-12-en-28-oic acid methyl ester

13,3-(2-acetoxy)benzoyloxyiminoolean-12-en-28-oic acid methyl ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In 1,4-dioxane at 20℃;93.9%
With dicyclohexyl-carbodiimide In chloroform at 0 - 20℃; for 2h;67%
With dicyclohexyl-carbodiimide In 1,4-dioxane at 20℃;

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields